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Introduction
Sarcopenia (age-related muscle loss) is a major care prob-
lem and is becoming more serious as average life expectancy
increases.  The  most  obvious  reason  is  that  when  muscle
function in the elderly declines they cannot generate enough
power to correct their posture quickly enough and they tend
to fall over and break bones that are brittle due to osteo-
porosis.  Muscles  generate  the  mechanical  strain  that  is
required to make the bones healthy. Therefore when muscle
activity  is  reduced  ,  this  exacerbates  the  problem  and  a
vicious circle is established. Another perhaps less obvious
function of muscle is that it acts as a metabolic store and in
times of emergency it produces the proteins and metabolites
required for survival. Therefore the frail elderly person who
has decreased muscle mass does not survive major surgery or
a traumatic accident. The muscle cachexia associated with
certain diseases e.g., cancer, HIV, makes this an even greater
problem as medication might have time to work if the tissue
loss could be prevented.
The work of my group over the last 10 years has been to
identify  the  factors  that  are  involved  in  inducing  muscle
hypertrophy and loss particularly during ageing and in cer-
tain  neurological  conditions.  As  well  as  marked  atrophy
there is a loss of muscle fibers. Damage to the innervation
occurs throughout life but in old age the process of collater-
al sprouting of the neurons appears to become less effective
in repairing innervation and muscle fibers are lost
1,2. As the
loss of muscle function is largely related to loss of muscle it
was important to determine which growth/repair factors are
involved in the molecular regulation of muscle mass and why
their levels or effectiveness decrease.
Cloning of MGF and other IGF-I splice variants
expressed by human muscle
About 12 years ago our group set about cloning these
growth factor(s) and identifying the genes involved in regu-
lation of muscle mass. For this purpose we needed to have
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an animal model in which we could make a muscle grow rap-
idly. Previous work had shown that if the tibialis anterior in
the mature rabbit was electrically stimulated whilst held in
the  stretched  position  by  plaster  cast  immobilisation  it
increased in mass by 35% within 7 days
3. The mRNA in the
stretch/stimulated muscles increased considerably but most
of this was ribosomal RNA. Using the differential display
with RT-PCR technique it was possible to detect an RNA
transcript that was only expressed in the stretched/stimulat-
ed muscle and not in resting control muscles. This transcript
was cloned and sequenced and when compared to sequences
in the gene data bases it was seen to be derived from the
insulin-like growth factor gene by alternative splicing. The
terminology of the IGF-I splice variants is a problem when
attempting to apply it to non hepatic tissues
4 and therefore
we  named  this  newly  discovered  splice  variant  "mechano
growth  factor"  (MGF)  as  it  is  expressed  in  response  to
mechanical  stimulation
5,6 and  as  it  has  a  different  down-
stream sequence to the liver type of IGF-I.
The  sequence  of  the  splice  variant  which  we  called
mechano growth factor (MGF) proved to be extremely inter-
esting not only because its expression was mechanosensitive
but because it has a different carboxy peptide sequence. It
was noted that its E domain has an insert in exon 5 that
changes the reading frame. In the rat there is a 52 base insert
and in the human the insert is 49 bases. Amino acids are
coded for by triplets of bases and because this insert which is
not a multiple of 3, is spliced into the MGF mRNA, then the
down stream peptide sequence is different from that of the
other IGF-I isoforms. This has important functional conse-
quences as the different IGF-I carboxy peptide sequences are
involved in the recognition of binding proteins. These sta-
bilise and act as a time release for these growth factors. Also,
in the case of MGF the carboxy peptide sequence (encoded
in exons 5 and 6) acts as a different growth factor to the IGF-I
receptor domain (exons 3 and 4). The E domain peptide has
been shown to induce division of mononucleated myoblasts
i.e.  to  activate  the  muscle  satellite  (stem)  cells  that  are
required for muscle hypertrophy and repair
7.
The  systemic  type  of  IGF-I  (IGF-IEa)  is  expressed  by
many cell types including skeletal muscle. This or the mature
IGF-I (IGF-I receptor domain) which is the commercially
available recombinant IGF-I that has been used in a good
number of in vitro and in vivo studies. The IGF-IEa cDNA
has been used to produce transgenic mice
8 and also introduce
into muscle by direct injection using a viral vector
9,10. In these
publications the expression has been described as muscle spe-
cific. This  is  misleading  as  muscle  promoter/enhancer
sequences  were  used  in  order  to  obtain  muscle  specific
expression. This is compounded by the fact that when the full
length cDNA of IGF-IEa was used this presumably included
the  carboxy  peptide  sequence  and  this  recognises  IGF-I
Figure. Splicing of the IGF-I gene as a result of exercise and/or muscle damage and hormones. In human muscle a 49 base insert changes
the reading frame in MGF resulting in a different carboxy peptide. Hormones upregulate the expression of the IGF-I gene particularly the
IGF-IEa but growth hormone (GH) apparently upregulates the primary RNA transcript of the IGF-I gene, and when in combination with
exercise training, it results in more being spliced towards MGF. Human muscle also expresses an IGF-IEb form but its function is not
known. The IGF-receptor domain encoded by exons 3 and 4, is responsible for the anabolic effect of IGF-I in all these splice variants.G. Goldspink: Genes and age-related muscle loss
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binding  proteins.  These  include  BP3  and  BP5  which  are
expressed in muscle and they tend to retain the systemic type
of IGF-I within the tissue. As far as can be discovered, the
IGF-I cDNA used in these gene transfer experiments
10 was
the systemic or liver type of IGF-I. Although this has a gen-
eral anabolic effect, the induced hypertrophy takes months
to develop in contrast to MGF where the same increase in
muscle mass can be achieved in a few weeks. In the latter
case the extra potency is apparently because MGF activates
the muscle satellite (stem) cells and this "kick starts" the re-
building process.
The role of MGF in renewing the muscle satel-
lite (stem) cell pool
Satellite cells in skeletal muscle were first described by
Mauro
11 and it is now realized that these cells provide the
extra nuclei for post-natal growth
12,13 and that they are also
involved in repair and regeneration following local injury of
muscle  fibres
14.  In  normal  adult  undamaged  tissue,  the
satellite  cells  are  quiescent  and  usually  detected  just
beneath the basal lamina. When activated they commence
to co-express myogenic factors including c-met, MyoD and
myf5  and  later  myogenin
15,16,17.  Satellite  cells  are  for  the
most  part  residual  myoblasts  although  other  pluripotent
stem cells have been shown to fuse and adopt the muscle
phenotype  when  introduced  into  dystrophic  muscle  and
damaged muscle. It has been established that even in nor-
mal muscle, local injury does occur from time to time
18, but
in certain diseases such as the muscular dystrophies, the
muscle fibers are markedly more susceptible to damage, in
particular  to  the  membrane
19.  The  contractile  system  of
muscle fibers also sustains damage during eccentric con-
tractions, that is to say, when the muscle is activated whilst
being stretched. It is interesting to note that the forces gen-
erated  by  activation  combined  with  stretch  exceed  even
those  of  a  maximal  isometric  contraction.  In  the  muscle
fibers involved, the sarcomeres may be pulled out to such a
degree that there is no longer any overlap of the actin and
myosin filaments, thus causing damage
20.
Two recent studies have indicated that one of the special
functions of MGF is to induce the muscle satellite (stem)
cells to divide. When IGF-I was added to C2C12 cells in cul-
ture  they  increased  in  mass  but  they  also  fused  to  form
myotubes. When the MGF E domain was added, then the
mononucleated myoblasts increased in number but stayed as
mononucleated cells. This effect, unlike the action of IGF-I,
was not blocked by an antibody to the IGF-I receptor indi-
cating that the MGF carboxy peptide is a growth/repair fac-
tor in its own right
7.
Using an in vivo approach, Hill and Goldspink
21 showed
that following muscle damage MGF is produced as a pulse
lasting a few days only. Although, it has been stated that
IGF-I activates satellite cells it was not certain from these
other studies whether this refers to inducing fusion of the
satellite cells rather than proliferation or indeed what type of
IGF-I was used. In our studies on local muscle damage, it
was  found  that  the  expression  of  MGF  preceded  that  of
markers of satellite cell activation. On the other hand, IGF-
IEa did not peak until 11 days after the damage, by which
time satellite cell activation had virtually ceased.
Failure to maintain muscle loss during ageing
and disease
Muscle  loss  (sarcopenia)  is  one  of  the  most  obvious
effects of ageing. The work of Owino et al.
22 indicated that
muscles in old rats, when surgically overloaded, were much
less able to express MGF than those in younger animals.
This was extrapolated to the human by Hameed et al.
23 who
showed that the muscles in elderly male volunteers when
exercised, were much less able to increase MGF levels as
compared  to  muscles  of  young  men.  None  of  the  other
parameters measured showed a marked age-related decline
although  it  has  previously  been  known  that  circulating
growth hormone levels in the over 70’s are much lower than
those  in  teenagers
24.  Whilst  it  was  clear  that  mechanical
activity plays a pivotal role in regulating local IGF-I expres-
sion in muscle, it was unclear as to whether there may be fur-
ther regulation provided by hormones, notably growth hor-
mone (GH). Some insight into this possibility was gained
from the results of a recent longitudinal study where the
relationship  between  exogenous  GH  administration  and
strength training exercise was studied in older people (age 74
± 1 year). These were assigned to either resistance training
with placebo, resistance training combined with GH admin-
istration  or  GH  administration  alone.  GH  administration
without training did not change MGF mRNA levels when
measured at 5 weeks, but significantly increased IGF-IEa
levels (237%). In contrast, 5 weeks of resistance training sig-
nificantly  increased  expression  of  MGF  (163%)  and  to  a
lesser extent IGF-IEa (68%). However, when GH treatment
was combined with exercise, MGF levels were dramatically
increased (456%). These data suggest that exogenous GH
administration causes an overall upregulation of transcrip-
tion of the IGF-I gene prior to splicing, which results in more
of the primary transcript of IGF-I. In the absence of strength
training exercise, splicing is towards the IGF-IEa isoform,
but when combined with the mechanical loading it splices
towards the MGF isoform.
Muscle loss is a major problem in certain hereditary dis-
eases. In dystrophic muscles it seems that there is an inabili-
ty to produce MGF in response to mechanical overload
25.
The systemic type of IGF-IEa is also produced by muscle,
including  dystrophic  muscle,  but  MGF  is  apparently
required  to  ensure  muscle  fiber  repair  and  survival.
Therefore the role of the IGF-I splice variant MGF seems to
be very relevant to understanding the etiology and the devel-
opment of possible treatment in these muscle wasting condi-
tions as well as sarcopenia.G. Goldspink: Genes and age-related muscle loss
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The role of MGF in other musculoskeletal tissues
Emerging evidence has indicated that MGF can be regard-
ed  as  a  cellular  repair  factor  as  well  as  a  growth  factor.
Effective local tissue damage limitation and the initiation of
local  repair  is  particularly  important  in  post-mitotic  tissues
such as muscle and neuronal tissue in which cell replacement
is not a means of tissue repair. In these tissues, cell death must
be prevented and repair initiated otherwise the ensuing cell
death will result in a progressive loss of function. It was known
that the myocardium expresses higher levels of IGF-I following
ischemia or mechanical overload. This was shown using a gen-
eral IGF-I antibody. However, recently we found that the type
of IGF-I expressed in these circumstances is MGF. By trans-
fecting cardiomyoctyes in culture using the Green Fluorescent
Protein sequence attached to the 3’ end of the cDNAs of MGF
and  IGF-IEa,  that  MGF  becomes  rapidly  localized  in  the
nucleus whilst the IGF-IEa peptide is localized through the
cytoplasm. In vivostudies of ischemia and mechanical overload
indicate that MGF reduces the size of the damaged area of the
myocardium and this is in accord with the finding that MGF is
expressed rapidly after tissue damage and prevents apoptosis.
The other type of tissue in which we have found MGF is neu-
ronal tissue. Recent work with a Polish group has shown that
MGF ameliorates the effects of ischemia to the brain where we
have  shown  it  is  expressed,  particularly  following  damage.
Neuronal tissue, as well as muscle, is post-mitotic tissue, and
cell replacement is not a means of tissue repair. It appears that
in the CNS, which is also a post mitotic tissue, MGF may have
a similar role of ameliorating damage limitation and also pos-
sibly initiation of the repair processes. As MGF was involved in
muscle repair, we thought that it may also be involved in main-
taining the peripheral neurons particularly in re-innervation of
muscle following damage. To investigate this we teamed up
with  Giorgio  Terenghi’s  group  at  the  University  of
Manchester, who has expertise in peripheral nerve repair. The
approach involved cutting the sciatic nerve and putting the two
cut ends in a conduit or nerve guide with a 2mm gap between
the two stumps. The conduit was filled with a gel containing
MGF,  or  IGF-IEa  or  the  vector  only.  MGF  was  found  to
induce  axonal  growth  over  the  gap  and  to  restore  muscle
strength to 99% of normal muscle within 3 months following
complete section of the nerve. The conduit with gel only con-
trols was effective in promoting re-innervation as about 70% of
the normal muscle function was restored. This demonstrates
the need for bringing the two cut ends of the nerve into juxta-
position so the proximal axons can grow down the sheaths of
the distal part. Further studies have shown that one of the ways
in which MGF enhances re-innervation is by causing axonal




As far as skeletal muscle is concerned, MGF is a splice
variant of the IGF-I gene that is expressed early following
muscle overload and/or damage. This results in the initial
activation of the skeletal muscle satellite (stem) cells which
fuse with the muscle fibres and donate nuclei. In this way
MGF initiates the hypertrophy process via which they adapt
to the type of physical activity they are required to perform.
The second phase involves the splicing of the IGF-I tran-
script towards the systemic or liver type or IGF-IEa which
provides more of the mature IGF-I. This produces the main
anabolic response that upregulates gene expression in gen-
eral. The evidence indicates that this is the mechanism via
which muscle mass is locally regulated and the inability to
express MGF in the elderly provides an explanation for the
decline in muscle function during ageing.
Exercise is also known to elevate the serum levels of
IGF-I
27,28. Not only are the muscles producing more systemic
IGF-I than the liver, they are also responsible for utilizing
more during intensive exercise. As the IGF-IEa and its bind-
ing proteins 3 and 5 are expressed by muscle and upregulat-
ed by exercise it means that the IGF-IEa will bind to these
binding proteins. Therefore, as this form of IGF-I is expect-
ed to have more effect on the muscles that produce it than
on other muscles, its action can be regarded as paracrine as
well as endocrine. The uptake from the serum seems to be a
consequence of the greater abundance of the specific bind-
ing protein in trained muscle. The increase in circulating
IGF-I is also believed to be one of the reasons why exercise
is  beneficial  and  that  general  tissue  maintenance  has
improved.  There is considerable evidence that IGF-I may be
involved in the maintenance of the CNS and this may be the
reason why regular exercise improves cognitive function.
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